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Abstract
Human pluripotent stem cells are increasingly used for CRISPR-mediated gene
targeting in efforts to generate models of human diseases. This is a challenging
task because of the high sensitivity of these cells to suboptimal conditions,
including CRISPR-associated DNA damage and subsequent rounds of
single-cell cloning. We sought to develop a sensitive method that enables rapid
screening of CRISPR targeted cells, while preserving cell viability and
eliminating the need for expensive sequencing of a large number of clones. A
protocol was designed in which the luminescent peptide tag, HiBiT, is
appended to the extracellular portion of an inert surface membrane protein
(CD46), using synthetic CRISPR reagents and a widely distributed human
induced pluripotent stem cell (iPSC) line. We find that this approach
substantially reduces labour-intensive screening of CRISPR-targeted iPSCs
and minimises the number of subcloning steps. Successfully edited iPSCs
could be identified within a week of targeting, based only on extracellular
luminescence detection in live cells. The total screening time in each round was
less than 30 minutes and no sequencing was required. This method can be
developed further to serve as a highly sensitive co-selection strategy in
CRISPR knock-in experiments, particularly in the context of challenging cell
lines.
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Introduction
The development of powerful gene editing technologies such as 
clustered regularly interspaced palindromic repeats (CRISPR)/
Cas9, alongside continuously improving protocols for the 
derivation and maintenance of induced human induced pluripo-
tent stem cells (iPSC), have made this cell type the model of 
choice in many settings, be it mechanistic disease studies or high- 
throughput screens aimed at identifying novel drug targets1.
Gene editing in human iPSCs is particularly powerful when 
applied to generation of series of isogenic cell lines differing 
only with respect to a specific pathogenic mutation. The technol-
ogy also enables tagging of endogenous proteins for studies that 
require differential cell labelling or the ability to pull down a 
target of interest. Nevertheless, such knock-in experiments 
remain challenging in human iPSCs, in part due to their sensitiv-
ity to CRISPR-induced DNA damage2 and poor survival as single 
cells3. Without bona fide selection, homology-directed repair 
(HDR) rates lower than 1 % are considered normal for human 
iPSCs and require picking of a relatively large number of individ-
ual colonies, or several rounds of sib-selection with subcloning4–6. 
This makes gene editing in human iPSCs costly because of 
expensive cell culture materials and the need for extensive 
sequencing of individual clones.
Faced with this challenge and the need to tag an extracellu-
lar surface protein for differential cell labelling, we sought to 
develop a method that allows for faster and cheaper screening of 
successfully targeted iPSCs, while minimising exposure to subop-
timal culture conditions. Given the low HDR efficiency in human 
iPSCs, such a method would have to be highly sensitive in order 
to distinguish the presence of rare gene-edited cells in a mixed 
population consisting mainly of wild-type counterparts. Thus, 
we focused on adapting the HiBiT luminescence technology 
for efficient screening and co-selection of human iPSCs under-
going dual targeting. The HiBiT technology comprises a split 
version of the exceptionally bright NanoLuc luciferase. A small 
11 amino acid peptide, HiBiT, can be fused to a protein of inter-
est, and subsequent supplementation with the large subunit 
(LgBiT) results in strong binding to HiBiT, thereby reconstituting 
NanoLuc activity. CRISPR-mediated HiBiT tagging and lumi-
nescence detection were recently used to track HIF1α dynamics 
in response to a range of stimuli, demonstrating the high sen-
sitivity of this method in HEK293, HeLa and primary human 
umbilical vein endothelial cells7. Importantly, the high sensitiv-
ity of the HiBiT system enables detection of very low amounts of 
target protein, down to femtomoles or lower7.
A major advantage of this technology emerges when the tag is 
appended to the extracellular portion of a surface membrane pro-
tein because this allows luminescence detection of gene-edited 
cells without the need for cell lysis and DNA extraction for 
downstream PCR-based applications. Here, we demonstrate that 
tagging of the extracellular portion of the cell surface protein 
CD46 allows for efficient and cost-effective screening of CRISPR-
targeted human iPSCs, reducing processing time to less than 30 
minutes per round, eliminating the need for expensive genetic 
assays and minimising stress-inducing cell manipulations.
Methods
Routine cell culture
We used the male iPSC line WTC11 (Coriell # GM25256) due 
to its amenability to genome editing and known diploid karyo-
type. WTC11 whole-exome and wholegenome sequencing data 
are available via the Conklin lab website.
Prior to targeting, the cells were cultured in 6-well plates coated 
with hESC-qualified Geltrex (Thermo Fisher Scientific # 
A1413302) diluted 1:100 in DMEM/F12 (Sigma # D6421). Cells 
were maintained in Essential 8 Flex (E8/F) medium (Thermo 
Fisher Scientific # A2858501) and passaged every four days when 
80-90 % confluent, with split ratios ranging from 1:10 to 1:15. 
ReLeSR (Stem Cell Technologies # 5872) was used to disso-
ciate the cells nonenzymatically, and 1X RevitaCell (Thermo 
Fisher Scientific # A2644501) was included during the first 
24 hours to promote survival.
Targeting design
We chose the human protein CD46 (ENSEMBL gene id: 
ENSG00000117335) for tagging because it is mainly involved 
in autologous cell protection against the complement system as 
well as acting as a costimulatory factor for T-cells to promote 
CD4+ T cell differentiation (Uniprot P15529); it is thus unlikely 
that tagging of this protein’s extracellular portion will interfere 
with important biological functions of human iPSCs and most 
of their differentiated derivatives. We used our previously pub-
lished RNAseq dataset to confirm that the gene is well-expressed 
in WTC116.
CD46 is a single-pass type I membrane protein, with the 
N-terminus exposed on the extracellular side of the plasma mem-
brane. The first 34 amino acids correspond to an endoplasmic 
reticulum (ER)-targeting signal sequence, which is cleaved from 
the mature protein. Consequently, the tag has to be knocked in 
after the signal peptide to avoid downstream removal. We used a 
published three-dimensional structure of CD46 (PDB ID: 1CKL) 
to confirm that this region is not buried within the protein upon 
folding. According to our strategy, successful targeting would 
result in tagging of 15 of the 16 CD46 isoforms. A flexible triple 
Glycine (GGG) linker was inserted between the tag and the start 
of CD46’s extracellular portion. This linker cannot be cleaved by 
chymotrypsin, factor XA, thrombin or trypsin (checked against the 
SynLinker database).
For guide RNA design, the following 240 bp sequence was sub-
mitted to the CRISPRko module of the Broad Institute’s GPP 
web tool8 (accessed 1 October 2018):
5 ’ - T G C T A T G A G C A C T C A G G T A A A A G C A 
TGGAACAGTCATTT AAAATCTTGCCAAGGGCCTTTCTGTT 
TTTTCTGTACTACCT GCTGCCAGACCACAGTCCATGGCTG 
ATGAAAGTGATATCAG TACTTCATCTTCATGTTCCTATTCT 
CTTATCCCTAGATGCCTG TGAGGAGCCACCAACATTTGAA 
GCTATGGAGCTCATTGGT AAACCAAAACCCTACTATGAGA 
TTGGTGAACGAGTA-3’
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Two guide RNAs from the output list were selected based on their 
on- and off-target ranks as well as cut distance from the insertion 
site. One of these, annotated sgRNA_CD46_rank13 (Table 1), was 
chosen for sub-sequent tagging experiments as it has previously 
been validated by IDT (Design ID: Hs.Cas9.CD46.1.AF).
Two 200 bp long HDR templates were designed manually, either 
including a sequence for HiBiT or a V5 tag (Table 1), followed 
by the flexible GGG linker. All three templates were designed 
asymmetrically following established rules9, using a shorter homol-
ogy sequence to the PAM-distal region and complementarity to 
the nontargeted strand. Known WTC11-specific SNPs in 
the targeted CD46 region were taken into account following 
examination of the publicly available WTC11 whole-genome 
sequence. No silent mutations were introduced into the template 
because successful tagging destroys the PAM site, thus prevent-
ing repeated targeting. Using ExPASy’s PeptideCutter tool, we 
confirmed that the translated fusion products wouldn’t be targeted 
by intracellular proteases.
Preparation of CRISPR/Cas9 targeting reagents
Single-stranded oligo DNA (ssODN) templates, ALT-R XT 
CRISPR RNA (crRNA), ALT-R trans-activating crRNA 
(tracrRNA) and ALT-R Cas9 Nuclease V3 were acquired from 
Integrated DNA Technologies (IDT).
Prior to use, the crRNA and the tracRNA were resuspended in 
pH 7.5 TE buffer (IDT # 11-01-02-02) to a final concentration of 
100 µM. To prepare crRNA:tracRNA duplexes at 50 µM, equal 
volumes of each RNA were mixed and heated for 5 minutes at 
95 °C, followed by controlled cool-off to 25 °C at ramp rate 
0.1 °C/second. The formed duplexes were placed on ice until 
ready to use.
Ribonucleoproteins were prepared by mixing 5 µl each of 
crRNA:tracRNA duplex (50 µM) and recombinant Cas9 enzyme 
(61 µM), followed by incubation at room temperature for 
20 minutes. Next, 200 pmol of each HDR template was added 
to the RNPs prior to delivery into iPSCs.
Nucleofection and luminescence-based screening of 
CRISPR-targeted iPSCs
Targeting was performed using healthy, subconfluent iPSCs 
(P51) pretreated with 1X RevitaCell (in E8/F) for 3 hours. The 
cells were dissociated with StemPro Accutase (Thermo Fisher 
Scientific # A110501) and 1e6 cells taken forward for nucleofec-
tion. Following low-speed centrifugation (100G, 3 minutes), the 
cell pellet was resuspended in 100 µl nucleofection solution 
(P3 Nucleofection Kit, Lonza # V4XP-3024). Of this suspen-
sion, 85 µl were transferred to the assembled RNPs, resulting 
in c. 850,000 cells in the final reaction. The nucleofection was 
carried out with an Amaxa 4D nucleofector, using programme 
CA137. Immediatley following nucleofection, 500 µl E8/F 
with 1X RevitaCell were added to the cell suspension and 
transferred to a Falcon tube containing 4.5 ml E8/F with 1X 
RevitaCell. Of this suspension, 100 µl were seeded into each well 
of a Geltrex-coated opaque-white Nunc 96-well plate (Thermo 
Fisher Scientific # 165306). The following day, the cells were 
replenished with 200 µl fresh E8/F without RevitaCell and 
again on day 3 post-nucleofection.
Luminescence-based screening for successfully targeted cells was 
carried out 4 days post-nucleofection, using Promega’s Nano-Glo 
HiBiT Extracellular Detection System. Briefly, the iPSCs were 
washed once with 200 µl DPBS per well, followed by addition 
of 50 µl DPBS. Next, 50 µl Nano-Glo HiBiT and LgBiT mixture 
were added to each well, followed by mixing and detection of 
the luminescent signal within 10 minutes, during which time the 
plate was kept away from light. Luminescence was detected on a 
BMG Clariostar, using top reading with lid to preserve sterility. 
The focal height was set to 11, and integration time was 1 second. 
Immediately following detection, the cells were transferred 
back to the biosafety cabinet and the solution removed from 
each well. Following a single wash in 200 µl DPBS, each well 
was replenished with 200 µl fresh E8/F. Although cell survival 
was not compromised with this procedure, we recommend the 
use of PBS with Ca2+/Mg2+ in future repeats as we noted that 
prolonged exposure to DPBS caused transient dissolution of 
cell-cell contacts within individual colonies.
Following recovery for 1-2 days, cells with a positive lumines-
cence signal were expanded non-enzymatically (using ReLeSR) 
into a Geltrex-coated 24-well plate, prior to a round of subclon-
ing into Geltrex-coated 96-well plates, seeding 12.5 cells/well 
in E8/F supplemented with 1X RevitaCell. From previous 
work, we know that this seeding density typically results in 
survival of 2-3 cells in each well and allows for efficient enrich-
ment while minimising cell loss6. RevitaCell was removed 6 
days post-subcloning and the cells processed for a second round 
Table 1. ALT-R XT CRISPR RNA (crRNA) and 
single-stranded oligo DNA (ssODN) sequences 
for CD46 targeting.
Description Sequence
crRNA-CD46 5’-AAATGTTGGTGGCTCCTCAC-3’
ssODN-
CD46-HiBiT
5’-GTACTACCTGCTGCCAGACC 
ACAGTCCATGGCTGATGAA 
AGTGATATCAGTACTTCATC 
TTCATGTTCCTATTCTCTTAT 
CCCTAGATGCCGTGAGCGGC 
TGGCGGCTGTTCAAGAAGAT 
TAGCggaggtggaTGTGAGGA 
GCCACCAACATTTGAAGCTA 
TGGAGCTCATTGGTAAACC 
AAAACCCTACTATGAGATTG-3’
ssODN-
CD46-V5
5’-GTACTACCTGCTGCCAGACC 
ACAGTCCATGGCTGATGAA 
AGTGATATCAGTACTTCATC 
TTCATGTTCCTATTCTCTTAT 
CCCTAGATGCCGGTAAGCCTA 
TCCCTAACCCTCTCCTCGGTC 
TCGATTCTACGggaggtggaTG 
TGAGGAGCCACCAACATTTGAA 
GCTATGGAGCTCATTGGTAAAC 
CAAAACCCTACT-3’
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of luminescence-based screening once most wells in a plate 
contained at least one colony with diameter > 1000 µm.
PCR-based detection of CRISPR-mediated CD46 tagging
Genomic DNA (gDNA) was extracted from luminescence- 
positive cells before subcloning and was used for PCR ampli-
fication of the CRISPR-targeted CD46 locus (F primer: 
5’-AAGTCCCATTTCCTCCACTAC-3’; R primer: 5’-ACAAGAA-
GAAAATCATCATCACCG-3’). The PCR was carried out using 
50-100 ng gDNA and GoTAQ G2 Colourless Master Mix 
(Promega) with the following thermocycling conditions (Techne 
Prime Thermal Cycler): 95 °C for 1 minute, 30 cycles of 95 °C for 
30 seconds - 60 °C for 20 seconds - 72 °C for 45 seconds, 72 °C 
for 45 seconds, 4 °C until collection. A FAM-labelled forward 
primer was used to enable detection of the PCR products (diluted 
1:20) by capillary electrophoresis. This was carried out on a 
LabChip GX24 Nucleic Acid Analyser (Perkin Elmer) using the 
DNA 1K Reagent Kit (Perkin Elmer #CLS760673) accord-
ing to the manufacturer’s instructions. Of note, prior to analysis, 
the PCR products were diluted 1:20 in nuclease-free water; 
this causes slower migration of the fragments due to low ionic 
strength. The correct size of the fragments was confirmed 
by conventional agarose gel electrophoresis (raw gel image 
included via OSF10). We suggest dilution in TE buffer in future 
repeats.
Results
We report preliminary work seeking to develop an efficient 
and highly sensitive high-throughput method for detection of 
successful CRISPR-mediated knock-in in human iPSCs. To do 
this, we co-targeted the cell surface protein CD46 with a HiBiT 
peptide and a V5 tag, followed by luminescence-based screen-
ing of live cells to identify cells with successful editing of 
at least one allele. The results are summarised in Figure 1.
Figure 1. HiBiT-tagging of the membrane surface protein CD46 enables rapid screening for successful CRISPR-mediated knockin in 
human induced pluripotent stem cells (iPSCs). a. Boxplots depicting the HiBiT luminescence signal distribution before and after subcloning 
of CRISPR-targeted cells in the indicated wells. The dashed red line marks the background signal threshold, chosen based on initial standard 
curve measurements using recombinant HiBiT protein (not shown). b. Capillary electrophoresis following PCR amplification of the targeted 
CD46 region in non-targeted control (NC) iPSCs and four HiBiT/V5-targeted iPSC populations prior to subcloning. While a clear band-shift 
can be resolved in targeted cells, the resolution is insufficient to distinguish between a V5 (+42 bp) vs a HiBiT (+32 bp) knock-in. c. Example 
light micrographs of iPSC colonies following one round of subcloning, revealing healthy colony morphology with clearly defined edges. Scale 
bar = 1000 µm.
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Prior to subcloning, the luminescence signal across wells with 
targeted cells exhibited a relatively broad distribution, with 
multiple wells reaching a signal just above background (set 
to 5000 light units) (Figure 1a). Only two wells had a signal 
between 10,000 and 15,000 light units. Cells from four wells with 
signal above 8000 light units were expanded, and two of these 
populations were subsequently used for subcloning into 96-well 
plates to enrich for HiBiT-positive cells. Within < 30 minutes, 
without the need for DNA extraction and Sanger sequencing 
of two 96-well plates, we were able to identify multiple wells 
with a substantial increase in luminescence signal relative 
to the overall population (Figure 1), indicative of successful 
enrichment. Importantly, we continued to use a stringent 
background threshold to limit the number of false positives.
PCR-based amplification of the targeted CD46 region in the origi-
nal four wells chosen for expansion was used to visualise the 
presence of a longer product (Figure 1b). While neither method 
has the capacity to confirm whether or not the V5 tag has been 
incorporated into the second allele, the successful expression 
of HiBiT on the cell surface strongly suggests that at least one 
allele was targeted correctly in a subset of the examined cells.
The extracellular luminescence detection in live cells was com-
patible with pluripotent stem cell survival, with subcloned cells 
retaining a healthy colony appearance upon outgrowth 
(Figure 1c). Thus, the enriched cells can be used for subsequent 
replica-plating and immunofluorescent detection of V5 with 
high-content imaging systems, substantially reducing expenses 
by only limiting detection to a few wells of a 96-well plate.
Discussion
CRISPR-mediated knock-in in human iPSCs remains a chal-
lenge due to low efficiency, poor cell survival and the resulting 
need to screen a large number of clones. Combined witht the 
high cost of human iPSC maintenance, relevant disease models 
based on this cell system are prohibitively expensive to many 
academic labs. We report a novel targeting strategy that utilises 
the HiBiT luminescence system to enable efficient screening 
for successfully CRISPR-edited iPSCs. The protocol uses live 
cells, thus eliminating the need for replica-plating, and can be 
executed within 30 minutes without compromising cell health.
Prior to applying this system, a standard curve should be 
generated using recombinant HiBiT-tagged protein in condi-
tions mimicking the final cell-based assay in order to estimate 
background levels. Although background levels may differ due 
to different kit lots and/or cell densities, keeping a conservative 
luminescence threshold across experiments is recommended to 
limit false-positive hits. It is notable that the luminescence signal 
distribution prior to subcloning was broad, but centred around 
the background threshold, which might reflect the high sensi-
tivity of the HiBiT system whereby the presence of rare cells 
with successful CRISPR-mediated knock-in of the tag can be 
picked up in multiple wells. It is important that future studies 
seeking to use this approach determine its compatibility as “co- 
selection” marker when the second targeting locus is distinct 
from CD46. It also remains to be determined whether CD46 
HiBiT-tagging will be equally efficient in other iPSC lines.
Finally, we note that this approach does not provide a quan-
titative measure of knock-in efficiency. The actual efficiency 
may be low overall, with detection in the current format only 
possible due to the high sensitivity of the HiBiT system. Although 
we were able to distinguish a CD46 band shift by PCR across 
the targeted region, detection of luminescence has the advan-
tage of confirming that the tagged protein is processed and 
expressed normally. This is a substantial improvement compared 
to conventional approaches based on laborious sequencing of 
a large number of clones to rule out unwanted indels in a 
CRISPR-targeted cell population.
Conclusions
The HiBiT luminescence system can be used as a powerful 
tool to screen for successfully CRISPR-edited human iPSCs in 
knock-in experiments. The method is fast, cost-effective and 
minimises stress-inducing cell manipulations. Our preliminary 
data encourage additional development of the protocol by 
researchers using CRISPR to knock in point mutations or smaller 
tags into iPSCs or other challenging cell types. The system is 
versatile and tagged cells will be compatible with a wide range 
of downstream assays, including intravital imaging.
Data availability
Underlying data
Open Science Framework: Luminescent peptide tagging for 
efficient screening of gene-edited human iPSCs. https://doi.
org/10.17605/OSF.IO/F82YD10
This project includes the following underlying data:
-2018-11-22CRISPRRNPCD46tagknockiniPSCsbeforesubcloningH 
yperladder100bp.tif(Gelimage,validationgel)
− 2018 − 12 − 01 − H11C3 −p54 − 96well − 25cells.per.well 
− to − replica − plate − 40x − 2.tif(Rawmicrographimage, 
C03Figure1C)
− 2018 − 12 − 01 − H11D3 − p54 − 96well − 12.5cells.per.
well − to − replica − plate − 40x − 1.tif(Rawmicrographimage, 
D03Figure1C)
2019-01-11Capelectrophoresisresultes.pptx (LabChipcapillaryelectr
ophoresisresults,withadditionaldescription)
LabChipGXRalitsa&Semple9DNA1ksamples11thJan2019.pdfLab
Chipcapillaryelectrophoresisrawoutputdata,Figure1B
−Rplotsforpublication.nb.html(RcodeunderlingFigure1a)
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−ReadmeLabChipCapElectrophoresisresults.pptx(additionalinforma
tionforinterpretationofFigure1B)
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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